Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Rating of “Moderate Buy” from Brokerages

Roivant Sciences Ltd. (NASDAQ:ROIV) has been assigned a consensus rating of “Moderate Buy” from the ten research firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $16.90.

Several equities research analysts have issued reports on ROIV shares. Wolfe Research began coverage on shares of Roivant Sciences in a research report on Thursday, February 15th. They set an “outperform” rating and a $17.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a report on Monday, April 22nd. Deutsche Bank Aktiengesellschaft increased their target price on Roivant Sciences from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. TheStreet upgraded Roivant Sciences from a “d” rating to a “c+” rating in a research report on Tuesday, February 13th. Finally, The Goldman Sachs Group upped their price objective on Roivant Sciences from $16.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd.

Roivant Sciences Trading Up 1.4 %

Shares of ROIV stock opened at $11.03 on Friday. The company has a market capitalization of $8.89 billion, a PE ratio of 2.12 and a beta of 1.34. Roivant Sciences has a 52-week low of $8.06 and a 52-week high of $13.24. The business’s fifty day moving average is $10.92 and its 200 day moving average is $10.37. The company has a debt-to-equity ratio of 0.06, a quick ratio of 27.79 and a current ratio of 27.79.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings results on Tuesday, February 13th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.07. The firm had revenue of $37.14 million for the quarter, compared to analysts’ expectations of $30.72 million. Roivant Sciences had a negative return on equity of 33.38% and a net margin of 3,624.14%. On average, equities research analysts anticipate that Roivant Sciences will post -1.36 EPS for the current fiscal year.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, COO Eric Venker sold 96,950 shares of Roivant Sciences stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $10.92, for a total value of $1,058,694.00. Following the transaction, the chief operating officer now directly owns 532,207 shares of the company’s stock, valued at approximately $5,811,700.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Roivant Sciences

Large investors have recently added to or reduced their stakes in the company. FMR LLC boosted its holdings in shares of Roivant Sciences by 8.1% during the third quarter. FMR LLC now owns 38,910,625 shares of the company’s stock worth $454,476,000 after purchasing an additional 2,913,491 shares during the period. Morgan Stanley lifted its holdings in Roivant Sciences by 48.7% in the 3rd quarter. Morgan Stanley now owns 19,311,631 shares of the company’s stock worth $225,560,000 after buying an additional 6,324,915 shares during the period. Rubric Capital Management LP grew its position in shares of Roivant Sciences by 81.0% in the 4th quarter. Rubric Capital Management LP now owns 19,000,000 shares of the company’s stock worth $213,370,000 after buying an additional 8,500,000 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Roivant Sciences by 159.1% during the third quarter. Vanguard Group Inc. now owns 5,602,566 shares of the company’s stock valued at $65,438,000 after buying an additional 3,440,374 shares during the period. Finally, Norges Bank purchased a new position in shares of Roivant Sciences during the fourth quarter valued at approximately $41,506,000. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.